Dr Michael Curtis PhD DSP FHEA FBPhS
Reader in Pharmacology
Research interests
- Pharmacology
Biography
I trained at the University of London (UK), and the University of British Columbia (Vancouver Canada). I have conducted research on cardiac arrhythmias and antiarrhythmic drugs for more than 30 years. I have served the British Pharmacological Society in a number of capacities, including senior editor of British Journal of Pharmacology (BJP), and champion of the journal’s design and analysis initiatives (see Br J Pharmacology 175 987-993, 2018).
Research
King’s Open Research Group Initiative (KORGI)
The King’s Open Research Group Initiative (or KORGI) is an action-oriented committee composed of an interdisciplinary mix of senior academics and experienced research staff that seek to change policy and procedures to promote transparent, accessible and reproducible research.
Status not setNews
Dr Louise Hesketh wins Cardiac Safety Early Career Seminar Award
A postdoctoral researcher in the School of Cardiovascular and Metabolic Medicine & Sciences has been presented with the Cardiac Safety Early Career Seminar...
New drug that may prevent sudden cardiac death without any side-effects
The new drug, named OCT2013, was found in animal experiments to prevent lethal arrhythmias and ventricular fibrillation as effectively as lidocaine but...
Assay validated for characterising a new drug for sudden cardiac death
A team of researchers from the School of Cardiovascular & Medicine Sciences have developed a novel antiarrhythmic drug that appears to be devoid of the...
Features
5 minutes with Michael Curtis
Dr Michael Curtis is a Reader in Pharmacology within the School of Cardiovascular Medicine & Sciences.
Research
King’s Open Research Group Initiative (KORGI)
The King’s Open Research Group Initiative (or KORGI) is an action-oriented committee composed of an interdisciplinary mix of senior academics and experienced research staff that seek to change policy and procedures to promote transparent, accessible and reproducible research.
Status not setNews
Dr Louise Hesketh wins Cardiac Safety Early Career Seminar Award
A postdoctoral researcher in the School of Cardiovascular and Metabolic Medicine & Sciences has been presented with the Cardiac Safety Early Career Seminar...
New drug that may prevent sudden cardiac death without any side-effects
The new drug, named OCT2013, was found in animal experiments to prevent lethal arrhythmias and ventricular fibrillation as effectively as lidocaine but...
Assay validated for characterising a new drug for sudden cardiac death
A team of researchers from the School of Cardiovascular & Medicine Sciences have developed a novel antiarrhythmic drug that appears to be devoid of the...
Features
5 minutes with Michael Curtis
Dr Michael Curtis is a Reader in Pharmacology within the School of Cardiovascular Medicine & Sciences.